Morpholinyl anthracyclines : option for reversal of anthracycline resistanceDE VRIES, E. G. E; ZIJLSTRA, J. G.European journal of cancer & clinical oncology. 1990, Vol 26, Num 6, pp 659-660, issn 0277-5379Article

Intensive chemotherapy and autologous bone marrow transplantation for solid tumorsPOSTMUS, P. E; DE VRIES, E. G. E.Monograph series of the European Organization for Research on Treatment of Cancer. 1984, Vol 14, pp 77-96, issn 0146-0447Article

The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumor typesPRINS, J; DE VRIES, E. G. E; MULDER, N. H et al.Anticancer research. 1993, Vol 13, Num 5A, pp 1373-1385, issn 0250-7005Article

Current state of liposome-complexed drugs in the treatment of cancer patientsDE VRIES, E. G. E; MULDER, N. H; DAEMEN, T et al.Annals of oncology. 1992, Vol 3, Num 6, pp 419-421, issn 0923-7534Article

The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycinMEIJER, C; MULDER, N. H; DE VRIES, E. G. E et al.Cancer treatment reviews. 1990, Vol 17, Num 4, pp 389-407, issn 0305-7372, 19 p.Article

A potential role of macrophage activation in the treatment of cancerKLIMP, A. H; DE VRIES, E. G. E; SCHERPHOF, G. L et al.Critical reviews in oncology/hematology. 2002, Vol 44, Num 2, pp 143-161, issn 1040-8428, 19 p.Article

Chemotherapy dose-escalation with hemopoietic growth factor support in ovarian cancerWILLEMSE, P. H. B; BOONSTRA, H; DE VRIES, E. G. E et al.Seminars in oncology. 1994, Vol 21, Num 6, pp 44-50, issn 0093-7754, SUP16Conference Paper

Antisense of oligunucleotides and the inhibition of oncogene expressionPRINS, J; DE VRIES, E. G. E; MULDER, N. H et al.Clinical oncology (Springer. Print). 1993, Vol 5, Num 4, pp 245-252, issn 0936-6555Conference Paper

Modulation of cis-diamminedichloroplatinum(II) resistance : a reviewTIMMER-BOSSCHA, H; MULDER, N. H; DE VRIES, E. G. E et al.British journal of cancer. 1992, Vol 66, Num 2, pp 227-238, issn 0007-0920Article

Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistanceDE JONG, S; ZIJLSTRA, J. G; MULDER, N. H et al.Cancer chemotherapy and pharmacology. 1991, Vol 28, Num 6, pp 461-464, issn 0344-5704Article

Mechanisms of cellular resistance to cisplatinHOSPERS, G. A. P; MULDER, N. H; DE VRIES, E. G. E et al.Medical oncology and tumor pharmacotherapy. 1988, Vol 5, Num 3, pp 145-151, issn 0736-0118Article

Effects of hematopoietic growth factors on chemotherapy-induced myelosuppressionBIESMA, B; VELLENGA, E; WILLEMSE, P. H. B et al.Critical reviews in oncology/hematology. 1992, Vol 13, Num 2, pp 107-134, issn 1040-8428Article

Alpha-fetoprotein-lectin binding as a marker of tumour activity or liver damageMARRINK, J; SLEIJFER, D. T; DE VRIES, E. G. E et al.European journal of cancer (1990). 1990, Vol 26, Num 9, pp 969-972, issn 0959-8049Article

Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell lineZIJLSTRA, J. G; DE VRIES, E. G. E; MULDER, N. H et al.Cancer research (Baltimore). 1987, Vol 47, Num 7, pp 1780-1784, issn 0008-5472Article

Twice weekly vindesine, a phase II study in lung cancerPOSTMUS, P. E; MULDER, N. H; SCHIPPER, D. L et al.Journal of cancer research and clinical oncology. 1987, Vol 113, Num 1, pp 99-100, issn 0171-5216Article

Human DNA topoisomerase II : Biochemistry and role in chemotherapy resistance (Review)WITHOFF, S; DE JONG, S; DE VRIES, E. G. E et al.Anticancer research. 1996, Vol 16, Num 4A, pp 1867-1880, issn 0250-7005Article

Recombinant human interleukin 3 in clinical oncologyDE VRIES, E. G. E; VAN GAMEREN, M. M; WILLEMSE, P. H. B et al.Stem cells (Dayton, OH). 1993, Vol 11, Num 2, pp 72-80, issn 1066-5099Article

The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell lineHOSPERS, G. A. P; DE VRIES, E. G. E; MULDER, N. H et al.British journal of cancer. 1990, Vol 61, Num 1, pp 79-82, issn 0007-0920Article

Influence of various beverages on urine acid outputDE VRIES, E. G. E; MEYER, C; STRUBBE, M et al.Cancer research (Baltimore). 1986, Vol 46, Num 1, pp 430-432, issn 0008-5472Article

Uptake mechanisms of L-3-[¹²⁵I]iodo-alpha-methyl-tyrosine in a human small-cell lung cancer cell line : comparison with l-1-[¹⁴C]tyrosineJAGER, P. L; DE VRIES, E. G. E; PIERS, D. A et al.Nuclear medicine communications. 2001, Vol 22, Num 1, pp 87-96, issn 0143-3636Article

Mutual interactions between P53 and growth factors in cancerASSCHERT, J. G. W; VELLENGA, E; DE JONG, S et al.Anticancer research. 1998, Vol 18, Num 3A, pp 1713-1725, issn 0250-7005Article

NMR spectroscopy analysis of phosphorus metabolites and the effect of adriamycin on these metabolite levels in an adriamycin-sensitive and -resistant human small cell lung carcinoma cell lineDE JONG, S; MULDER, N. H; DE VRIES, E. G. E et al.British journal of cancer. 1991, Vol 63, Num 2, pp 205-212, issn 0007-0920, 8 p.Article

Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancerMADURO, J. H; PRAS, E; WILLEMSE, P. H. B et al.Cancer treatment reviews. 2003, Vol 29, Num 6, pp 471-488, issn 0305-7372, 18 p.Article

The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospectsHOSPERS, G. A. P; EISENHAUER, E. A; DE VRIES, E. G. E et al.British journal of cancer. 1999, Vol 80, Num 5-6, pp 629-638, issn 0007-0920Article

Medical oncology in the next centuryDE VRIES, E. G. E; MULDER, N. H; SLEIJFER, D. T et al.Netherlands journal of medicine. 1999, Vol 55, Num 6, pp 310-315, issn 0300-2977Article